Use of Propranolol Hydrochloride in the Treatment of Metastatic STS
Fifty patients with pathological proof of malignant soft tissue sarcoma will receive Anthracyclin based chemotherapy combined with propranolol 40 mg twice daily.

* The primary end point : To assess Progression Free Survival (PFS)
* The secondary end points : To assess Overall Survival (OS) and Toxicity Profile
Malignant Soft Tissue Sarcoma
DRUG: Propranolol Hydrochloride|DRUG: Doxorubicin
Progression Free Survival, Progression free survival (PFS) is defined as the time interval between the dates of first treatment administration and first observation of PD., an average of 1 year
Overall Survival, Overall Survival (OS) is defined as the time from the date of the first treatment administration to the date of death due to any cause., an average of 3 years
Fifty patients with pathological proof of malignant soft tissue sarcoma will receive Anthracyclin based chemotherapy combined with propranolol 40 mg twice daily.

* The primary end point : To assess Progression Free Survival (PFS)
* The secondary end points : To assess Overall Survival (OS) and Toxicity Profile